An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus [1]

Clinical Infectious Diseases

Volumn 42, Issue 11, 2006, Pages 1652-1653

  Patel, Jean B ^a   Jevitt, Laura A ^a   Hageman, Jeffery ^a   McDonald, L Clifford ^a   Tenover, Fred C ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CELL WALL; BACTERIAL METABOLISM; BACTERIUM CULTURE; BACTERIUM ISOLATE; BROTH MICRODILUTION; CHI SQUARE TEST; CULTURE MEDIUM; DIFFUSION; GRADIENT DIFFUSION METHOD; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 33646741453     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/504084     Document Type: Letter

References (9)

1. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994-1000.
2. Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE Jr, Tenover FC. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcusfaecium. Microb Drug Resist 2003; 9:389-93.
3. CLSI. Performance standards for antimicrobial susceptibility testing: 16th informational supplement. CLSI document M100-S16. Wayne, PA: NCCLS, 2006.
4. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001;45:454-9.
5. Cui L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003;41:5-14.
6. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum R, Labischinski H, Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42: 199-209.
7. Tenover FC, Weigel LM, Appelbaum PC, et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48:275-80.
8. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-7.
9. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus-New York, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:322-3.